Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Quanyin Xiangyu Biotechnology is a specialized biotechnology company focused on the research, development, and production of high amylose corn and resistant starch products. Established as a strategic growth initiative of Quanyin Hi-Tech (300087.SZ), the company leverages advanced breeding technologies to produce functional food ingredients that support metabolic health. Its product portfolio includes various grades of resistant starch (RS2) designed for use in low-glycemic index (GI) foods, dietary supplements, and health products. With independent intellectual property over its corn varieties and research facilities in Sanya and Xinjiang, the company serves as a key supplier for the nutrition and health industries. Quanyin Xiangyu is ultimately controlled by Sinochem Holdings, reflecting its strong industrial and scientific foundation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Quanyin Xiangyu Biotechnology.